Research / ACCS / Fundamental state Inspectable configuration
State dimensions Filing 0001683168-26-006204 General Corporate
Debt relative to revenue 9th Own-history percentile · N=11
Evidence method Level · gp.fundamentals.debt_to_revenue
37.91% · OPTIONAL · VALID
Capex intensity 70th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.capex_revenue_ratio
0.23% · OPTIONAL · VALID
Operating cash generation 20th Own-history percentile · N=20
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
3.08% · OPTIONAL · VALID
Revenue growth 50th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.revenue
-0.05% · CORE · VALID
Gross margin 0th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.gross_margin
73.19% · CORE · VALID
Operating margin 20th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.operating_margin
-5.46% · CORE · VALID
R&D intensity 65th Own-history percentile · N=20
Evidence method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
9.49% · OPTIONAL · VALID
SBC intensity 25th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
2.60% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 70 states Self-history eligible
Sep 30, 2021 7/7 normalized Level 3 Dec 31, 2021 7/7 normalized Level 3 Mar 31, 2022 7/7 normalized Level 3 Jun 30, 2022 7/7 normalized Level 3 Sep 30, 2022 7/7 normalized Level 3 Dec 31, 2022 7/7 normalized Level 3 Mar 31, 2023 7/7 normalized Level 3 Jun 30, 2023 7/7 normalized Level 3 Sep 30, 2023 7/8 normalized Level 3 Dec 31, 2023 7/8 normalized Level 3 Mar 31, 2024 7/8 normalized Level 3 Jun 30, 2024 7/8 normalized Level 3 Sep 30, 2024 7/8 normalized Level 3 Dec 31, 2024 6/7 normalized Level 3 Mar 31, 2025 7/8 normalized Level 3 Jun 30, 2025 7/8 normalized Level 3 Sep 30, 2025 8/8 normalized Level 3 Dec 31, 2025 8/8 normalized Level 3 Mar 31, 2026 8/8 normalized Level 3 Jun 30, 2026 8/8 normalized Level 4 Period transition
What moved in the state? Balance Sheet Leverage Decreased
Previous 43.98%
Current 37.91%
Delta -6.07% Capex Intensity Increased
Previous 0.17%
Current 0.23%
Delta 0.06% Cash Generation Decreased
Previous 16.35%
Current 3.08%
Delta -13.27% Growth Increased
Previous -2.72%
Current -0.05%
Delta 2.67% Margin Decreased
Previous 74.17%
Current 73.19%
Delta -0.98% Profitability Increased
Previous -13.48%
Current -5.46%
Delta 8.01% R And D Intensity Decreased
Previous 10.51%
Current 9.49%
Delta -1.03% Sbc Intensity Decreased
Previous 4.96%
Current 2.60%
Delta -2.36% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Dec 31, 2019
Similarity 84%
Compared 7 dimensions
Coverage 88% Growth 30.0 · Margin 0.0 · Profitability 20.0 · Sbc Intensity 10.0 · Capex Intensity 15.0 · Cash Generation 15.0 · R And D Intensity 3.4 Mar 31, 2019
Similarity 76%
Compared 7 dimensions
Coverage 88% Growth 25.0 · Margin 0.0 · Profitability 20.0 · Sbc Intensity 10.0 · Capex Intensity 50.0 · Cash Generation 5.0 · R And D Intensity 16.3 Sep 30, 2025
Similarity 75%
Compared 8 dimensions
Coverage 100% Growth 25.0 · Margin 30.0 · Profitability 5.0 · Sbc Intensity 35.0 · Capex Intensity 35.0 · Cash Generation 20.0 · R And D Intensity 25.0 · Balance Sheet Leverage 9.1 Mar 31, 2018
Similarity 74%
Compared 7 dimensions
Coverage 88% Growth 10.0 · Margin 55.0 · Profitability 15.0 · Sbc Intensity 10.0 · Capex Intensity 10.0 · Cash Generation 5.0 · R And D Intensity 35.0 Dec 31, 2014
Similarity 68%
Compared 6 dimensions
Coverage 75% Growth 5.6 · Margin 70.0 · Profitability 25.0 · Sbc Intensity 9.6 · Capex Intensity 6.9 · Cash Generation 20.0 Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.